ライフサイエンスコーパス: consent to

1 mber of donor management goals achieved from consent to 12-18 hrs later (odds ratio=1.13 per addition

2 with elevated cancer risk and dense breasts consented to 3 annual independent screens with mammograp

3 Patients prospectively consented to 5 years of follow-up.

4 majority (83%) were willing to grant advance consent to a blood draw study, and nearly half (48%) to

5 the responsibility for advising a patient to consent to a cardiac operation using honestly presented

6 ity to appoint a research proxy, capacity to consent to a drug RCT, and capacity to consent to a neur

7 Each patient provided written consent to a human subject protocol approved by an insti

8 ty to consent to a drug RCT, and capacity to consent to a neurosurgical RCT.

9 sumed advanced ovarian cancer, were asked to consent to a postoperative CT scan if cytoreduction to <

10 Participants provided written informed consent to a protocol that was approved by a local resea

11 utinely to evaluate individuals' capacity to consent to a research protocol.

12 Subjects consented to a "study of diseases of public health impor

13 Of these, 125 consented to a follow-up transesophageal echocardiogram

14 ed paraffin-embedded (FFPE) tumour biopsy or consented to a new biopsy at screening for the analysis

15 between February 2003 and September 2005 who consented to a survey and medical record review (61% res

16 lant candidates (KTCs) must provide informed consent to accept kidneys from increased risk donors (IR

17 oard of the university, and written informed consent to acquire and analyze MR spectroscopic imaging

18 , after which >80% of surviving participants consented to additional active follow-up through Septemb

19 domized participants and censoring those not consenting to additional follow-up on March 31, 2005, es

20 The participants are also being consented to allow the contact of family members for add

21 the patient and the referring physician have consented to allow their data to be used for research.

22 sified) or grade I-IV COPD provided informed consent to an ethics board-approved HIPAA-compliant prot

23 rse events (AEs), participants were asked to consent to an extended follow-up phase in order to asses

24 tu hybridization of colon tissue-the patient consented to an analytic treatment interruption (ATI) wi

25 red because the donors had registered in and consented to an anatomic gift program prior to their dea

26 3 for up to 60 months in 6 of 8 patients who consented to an end-of-study biopsy.

27 o attended the final blinded study visit and consented to anal specimen collection were included in t

28 Seventy-two patients consented to analyses of tumor epidermal growth factor r

29 surviving children, 3324 were revisited and consented to anthropometric measurements.

30 lth-record abstraction were done for all who consented to ascertain potential interpersonal connectio

31 inical trial, 268 active-duty servicemembers consented to assessment at an army medical center from M

32 463 were randomly selected, and 267 (57.7%) consented to assessment of their HPA axis function.

33 articipants and a subset of ACT participants consent to autopsy.

34 nts with biopsy-proven PCa provided informed consent to be included in this institutional human ethic

35 linicians and patients provided full written consent to be interviewed and have appointments audio-re

36 Practices that did not consent to be randomly assigned comprised a practice-as-

37 d their donor card, one might consider their consent to be truly informed and valid.

38 igned to treatment as usual) were traced and consented to be assessed between July, 2013, and Septemb

39 Women in the pregnancy cohort who consented to be contacted for participation in future st

40 tween January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis

41 2100 participants in the CHHiP trial consented to be included in the QoL substudy: 696 assign

42 Of the 116 who consented to be included in the study, 112 (97%, 95% CI

43 , 134 accessed their results online, and 105 consented to be included.

44 or screening and 6369 (99.4%) of these women consented to be screened with the PHQ-9 (40 women did no

45 ified from an in-house database, 53 patients consented to be screened.

46 setting, a patient with open-angle glaucoma consented to be the recipient of the WIT in one eye in a

47 was conducted with 465 participating mothers consenting to be followed up at 3 years after interventi

48 y the 12 month follow-up and had given their consent to being re-contacted.

49 ne (18)F-FDG PET/CT for various malignancies consented to being scanned for CL.

50 r analyses were done on all treated patients consenting to biomarker analyses and providing a measura

51 and had a known BRAF(V600) mutant status or consented to BRAF(V600) mutation testing during screenin

52 RCT) scanning in an ongoing cohort study; 72 consented to bronchoscopy with bronchoalveolar lavage (B

53 tructured assessments of adults' capacity to consent to clinical treatment or research protocols.

54 riod were screened for eligibility; informed consent to collect baseline and outcome data was sought

55 enrolled were identified retrospectively and consented to compare survival in patients treated by sta

56 63 women with stillbirth enrolled, 500 women consented to complete postmortem examinations of 512 neo

57 aluation of dietary intake where 522 parents consented to completing >=1 component of data collection

58 Findings showed that the approach to gain consent to conduct the MITS procedure involves religious

59 Before consenting to copulate, a female fruit fly gauges both h

60 al invasive bacterial disease were asked for consent to culture their child's blood/body fluid.

61 Subjects gave consent to deposit phenotypic data and blood samples int

62 ents reported feeling adequately informed to consent to diagnostic genomic sequencing.

63 ractice for a nonprocedural office visit who consented to direct observation and 273 patients whose p

64 se, permit, or identification card increased consent to donate organs among white and black participa

65 LIMITATION: How the observed increases in consent to donate organs might translate into a greater

66 mily members who had recently been asked for consent to donate the organs of a deceased family member

67 More participants who viewed the video consented to donate organs than control participants (84

68 ) whether, when, and how to ask families for consent to donation or (b) characteristics of families o

69 ectives of requesting and encouraging family consent to donation, (2) the effect of the donation deci

70 erable barriers exist for Hispanic Americans consent to donation, resulting in significantly lower do

71 Twenty-seven families consented to donation and 20 successful organ donations

72 ne follow-up, and administration of informed consent to eligible women.

73 nd additional risk factors provided informed consent to enroll in an institutional review board-appro

74 oval for consenting processes or a waiver of consent to enroll participants, link data, and perform a

75 onsenting processes or to obtain a waiver of consent to enroll participants, link data, and perform a

76 s independently indicated whether they would consent to enroll the patient in the same scenarios.

77 entified with a functioning graft at 2 years consented to enroll in an observational, nonintervention

78 Seventy-one HT recipients consented to enroll.

79 atients were assessed for eligibility and 52 consented to enrolment.

80 more, had no contraindications to iuMRI, and consented to enter the study.

81 To determine how often study participants' consent to examine DNA is denied and the factors associa

82 The median time from informed consent to expression analysis was 11 days.

83 oman in the concealed testing group withdrew consent to follow-up data collection, so 446 (>99%) wome

84 or unavailability of the device (n = 4) but consented to follow-up and constitute a contemporaneous

85 luded in the original trial were located and consented to follow-up assessment.

86 tudy that enrolled 153 patients, of whom 111 consented to follow-up for 36 months.

87 urviving patients who were English speaking, consented to follow-up, and were randomized between Dece

88 nt for nonvirologic reasons and four did not consent to genetic testing.

89 drial haplogroups in A5005s participants who consented to genetic analyses.

90 nd phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samp

91 mbers of the FHS Omni cohort (n=160) who had consented to genomic studies.

92 egravir arm and 168 in the efavirenz arm who consented to genotyping.

93 e-designated comprehensive cancer center and consented to have information stored in a prospective da

94 with normal allograft function (n = 70) who consented to have serum samples collected for research p

95 6 participants who received active treatment consented to have their clinical and radiologic data inc

96 le patients responded to the survey, and 85% consented to have their medical records reviewed.

97 compliant study, which included patients who consented to having their medical records used for resea

98 equivocally capable of providing independent consent to higher-risk AD research, providing for an app

99 50 persons at risk for HIV infection who had consented to HIV testing presented at state-funded sites

100 6%) were offered PITC, of whom 1,534 (54.2%) consented to HIV testing.

101 who were HIV uninfected and sexually active consented to HIV-1 RNA testing twice a week and biologic

102 ated within the intensive care unit (n = 93).Consent to ICOD was obtained in 174 cases.

103 The majority of families (95%) consented to ICOD.

104 y of the interview, the majority of families consented to ICOD.

105 92 individuals (55%) consented to in-depth interview.

106 om repair hospital in all eligible women who consented to inclusion and could provide follow-up data.

107 fetal heart sound at time of admission, and consented to inclusion.

108 ares data from samples with a similarly open consent to increase the number of samples and population

109 (aOR 0.68,0.50-0.93 and 0.55,0.28-1.09), and consent to infant blood sample donation (n = 220[48%]) (

110 ipating to help children were more likely to consent to infant blood sample donation.

111 e, 1819 households (one adult per household) consented to initial contact by the study team.

112 The patient consented to join a clinical trial for metastatic TCC (U

113 ving cardiac surgery without a history of AF consented to left and right atrial biopsies and a pre-op

114 mpleted self-administered questionnaires and consented to linkage of questionnaire responses with adm

115 l study, 254 men who had been assigned to WW consented to longer-term follow-up.

116 ersons with AD who were thought incapable of consenting to lower-risk or higher-risk studies have pre

117 that affirm 18 years as the minimum age for consent to marriage, international human-rights standard

118 ves) used a smartphone (Apple iPhone) app to consent to monitoring.

119 o lacked a confirmed genetic diagnosis (55%) consented to NGS studies, leading to confirmed diagnoses

120 metropolitan areas provided written informed consent to obtain medical records from all providers who

121 December 6, 2005, and December 9, 2008, 215 consented to ongoing follow-up through at least 7 years

122 querying Siminoff's National Study of Family Consent to Organ Donation database, we find that this si

123 More people who have personally consented to organ donation via first person authorizati

124 Death was pronounced and the family consented to organ donation.

125 All subjects gave informed consent to participate and were examined using Diagnosti

126 f the follow-on clinical trial gave informed consent to participate in a longitudinal neuroimaging fM

127 vey to patients or surrogates approached for consent to participate in a minimal risk, ICU-based stud

128 for breast cancer, who gave written informed consent to participate in a study evaluating cancer dete

129 Signed consent to participate in an institutional review board-

130 Patients were asked whether they would consent to participate in hypothetical research studies

131 pacity of persons with mental retardation to consent to participate in randomized clinical trials.

132 fifty-seven individuals were approached for consent to participate in the parent study; none objecte

133 Parents and children gave informed consent to participate in the research.

134 Two patients withdrew their consent to participate in the study, and 5 patients were

135 and were able and willing to provide written consent to participate in the study.

136 s (age range, 52-65 years) provided informed consent to participate in this cross-sectional study.

137 Each subject gave written consent to participate in this HIPAA-compliant, institut

138 Each subject gave written informed consent to participate in this institutional review boar

139 Study participants provided written informed consent to participate in this institutional review boar

140 [standard deviation]) gave written informed consent to participate in this prospective ethics commit

141 Methods Fifteen women gave informed written consent to participate in this prospective HIPAA-complia

142 Subjects provided written consent to participate in this prospective institutional

143 All participants provided informed consent to participate in this study, which was approved

144 undred thirty-two students provided parental consent to participate in this trial.

145 , communal coping is evidenced through joint consent to participate, regular couple counselling and w

146 ofessional were significantly more likely to consent to participate.

147 ere significantly positively associated with consent to participate.

148 cs board, and all patients provided informed consent to participate.

149 , and 30 (1%) children whose mothers did not consent to participate.

150 negative on the PHQ-9, and one woman did not consent to participate.

151 The partners of these women also had to consent to participate.

152 negative on the PHQ-9, and one woman did not consent to participate.

153 evidence of having provided written informed consent to participate.

154 ia, and 634 (9.3%) provided written informed consent to participate.

155 identified, 1003 were eligible, of whom 625 consented to participate (n=335 exercise plus education

156 A total of 57 patients consented to participate and were enrolled.

157 Ninety-four patients consented to participate and were randomized (46 to plac

158 n Feb 28, 2000, and Sept 14, 2012, 292 women consented to participate and were randomly assigned to t

159 Of these, 300 consented to participate in a longitudinal follow-up stu

160 Participants were eligible if they had consented to participate in a phase I cancer study at on

161 ves of patients with pulmonary fibrosis (PF) consented to participate in a screening study that inclu

162 f 450, 205 previously sero-negative subjects consented to participate in a second stage of the study

163 Of 1033 eligible RYGB patients who consented to participate in longitudinal research and co

164 If women were not interested in PLCO but consented to participate in our study, they were intervi

165 Of the 1473 eligible residents, 953 consented to participate in the study (mean age, 86 year

166 Thirty-six of 50 sites (72%) consented to participate in the study, and 18 (50%) repo

167 A total of 79 individuals consented to participate in the study.

168 atients had died; 146 of 179 living patients consented to participate in the study.

169 11 case subjects and 553 comparison subjects consented to participate in the study.

170 ternal biorepository of 123 357 patients who consented to participate in the Total Cancer Care bioban

171 Of 149 eligible patients, 138 consented to participate in the trial and were randomly

172 or metastatic lesions in different locations consented to participate in this institutional review bo

173 he number of individuals (self-selected) who consented to participate was 48968, representing all 50

174 Those who met additional entry criteria and consented to participate were enrolled.

175 undergoing LASIK at the Duke Eye Center who consented to participate were imaged with Placido-ring t

176 Residency directors who consented to participate were informed of pertinent info

177 Those who consented to participate were informed of the nature of

178 All physicians consented to participate with an opt-in or opt-out mecha

179 Of the 285 participants consented to participate, 173 children completed the pro

180 Of 1132 women seeking abortion who consented to participate, 874 were included in this anal

181 irements for a screening breast US trial and consented to participate, scanned both breasts in all pa

182 ncluding Mohs micrographic surgery), (2) who consented to participate,and (3) who were able to be rea

183 y suspected SH1DF; 170 were eligible and 140 consented to participate.

184 for a mean of 10.8 years (range, 3-24 years) consented to participate.

185 d, responding pathologists were eligible and consented to participate.

186 dependent, and able to communicate, 83 (47%) consented to participate.

187 teams contesting during the 2012-2013 season consented to participate.

188 80 +/- 0.6 years; 49% male) undergoing TAVI consented to participate.

189 2004 to March 2005 were informed before they consented to participate.

190 breasts) with numerous known breast lesions consented to participate.

191 ient departments/ICU/operation room; and (3) consented to participate.

192 s (109 693 individuals) in the control group consented to participate.

193 nd fellows from a training program in Mexico consented to participate.

194 Twenty-seven of 82 patients consented to participate; 15 and 11 patients were assess

195 Of 6000 veterans telephoned, 1075 consented to participate; 405 of these had chronic pruri

196 t recruitment, 52.8% of eligible individuals consented to participate; retention was 93.2% one year l

197 Patients remaining alive and consenting to participate had a follow-up visit during 2

198 in hospital for more than 24h and who could consent to participating.

199 Fifty-two patients consented to participating in the study and 22 demonstra

200 h cancer can both understand and voluntarily consent to participation in a clinical trial involving m

201 ildren in the corresponding weight bands who consented to pharmacokinetic studies and received the st

202 ough a surrogate decision maker-and specific consent to premortem procedures has been given.

203 rst-degree relative signing a donor card, or consenting to procurement of organs after death.

204 Eighty-two percent consented to provide blood, 631 gave permission for DNA

205 s with stage III NSCLC randomized, 360 (85%) consented to QOL evaluation, of whom 313 (88%) completed

206 Of the 49 randomly assigned patients who consented to quality of life assessment (EPP n=23; no EP

207 d in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus I

208 factory response to citalopram, patients who consented to random assignment to either cognitive thera

209 4 patients invited to join the trial did not consent to randomisation; 722 were subsequently assigned

210 Difficulty obtaining patient consent to randomization is an important barrier to cond

211 Less than one-third of participants consented to randomization strata that permitted compari

212 ng by center RESULTS:: A total of 1163 women consented to receive 18-month questionnaires of whom 730

213 current trial, consecutive patients with MDD consented to receive MST applied over the prefrontal cor

214 e risk in 3/85 (3.5%) newborns whose parents consented to receive this information.

215 mplication data were collected, and patients consented to receive validated PRO questionnaires at 18-

216 47% of screened patients consented to recruitment.

217 s in phase 3 licensure trials, virtually all consented to registry-based long-term follow-up.

218 CS examination outcomes for students who had consented to release of their results.

219 September 2008 to September 2010, 958 women consented to repeat standard breast US supplemented by q

220 and a standardized RCC measure (Capacity to Consent to Research Instrument [CCRI]).

221 ) donor consent forms be expanded to include consent to research on organs and associated retrieved m

222 hical and practical challenges of adolescent consent to research participation in these countries.

223 ctive assessment of children's competence to consent to research participation is currently not possi

224 e capacities of neuropsychiatric patients to consent to research, yet few empirical investigations ha

225 d decision-making capacity and are unable to consent to research.

226 the institutional review board, and patients consented to research authorization.

227 If individuals incapable of consenting to research studies were able to appoint a re

228 f 48 patients with colorectal cancer who had consented to retrospective analysis of hepatic perfusion

229 anced PEComa were treated with sirolimus and consented to retrospective collection of data from their

230 for return and the research participant has consented to return, genomic results, along with referra

231 patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and geneti

232 Consent to share data was requested, anonymised for coun

233 g a large urban academic hospital system who consented to share access to their history of Facebook s

234 e more likely to attend research clinics and consent to skin-prick testing.

235 By contrast, the requirements for consent to storage and specified uses of samples are pre

236 Of the 611 patients consented to study enrollment, 380 met the inclusion cri

237 sample of adolescent MSM at risk for HIV who consented to study participation.

238 Participants consented to study procedures and provided usable activi

239 reak patients or their legal representatives consenting to study were enrolled between September 2002

240 eem to be a good potential mode of obtaining consent to supplement the harvesting of adequate tissues

241 Consent to surgery is regulated by the same common law p

242 The patient did not consent to surgical treatment.

243 loyees of the chosen organisations who would consent to take part in the study, participants with inf

244 All participants provided informed consent to take part in the trial.

245 students registered in the selected schools consented to take part in the study.

246 major depressive disorder were eligible and consented to take part.

247 d with a patient information sheet and those consenting to take part in the study received standardiz

248 Of 1042 eligible patients, 508 consented to testing.

249 232 (70.7%) of potentially exposed patients consented to testing; 2 were found to have acute infecti

250 Families are often asked to consent to the donation of their deceased relative's org

251 tients enrolled for SLN evaluation, 123 gave consent to the OSNA protocol and 156 to the standard his

252 ntify subjects with questionable capacity to consent to the specific research project.

253 al of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and

254 Four hundred ninety-eight patients consented to the biomarker analysis: 242 in the XELOX gr

255 he proportion of patients with chlamydia who consented to the online chlamydia pathway who then recei

256 (86%) competed the survey, including 94 who consented to the parent study and 41 who declined.

257 A total of 288 patients (> 96%) consented to the QoL substudy.

258 neae are prelevated from body donors who had consented to the removal of tissues for transplantation

259 eb 11, 2015, and March 2, 2017, 310 patients consented to the study at 22 sites.

260 Of the 69 patients who consented to the study, 39 underwent the follow-up fMRI

261 All 34 patients consented to the study, and 29 completed follow-up.

262 1 diabetes and recurrent severe hypoglycemia consented to the study, including standardized meal tole

263 n both groups, all eligible participants who consented to the treatment and were at least 90 cm in he

264 Screening Trial (NLST), and each participant consented to the use of their de-identified images for r

265 All included patients had previously consented to the use of their medical records for resear

266 All patients included had previously consented to the use of their medical records for resear

267 All patients included had previously consented to the use of their medical records for the pu

268 .7% (40 of 106) of those deemed incapable of consenting to the drug RCT and 54.8% (86 of 157) of thos

269 HIV status and ART coverage among adults not consenting to the intervention or HIV testing, although

270 lysis, acceptance of HIV testing among those consenting to the intervention was high, although linkag

271 the 45,399 (77%) men and 55,703 (90%) women consenting to the intervention, 80% of men and 85% of wo

272 Only 7 of 186 (3.8%) were deemed capable of consenting to the neurosurgical RCT by all 5 psychiatris

273 .8% (86 of 157) of those deemed incapable of consenting to the neurosurgical RCT were found capable o

274 e study from archival material from patients consenting to the use of medical records for research pu

275 Male guardians were less likely to consent to their child being tested.

276 None required explicit physician consent to their sharing policies.

277 rity of respondents reported they would have consented to their children being vaccinated if the vacc

278 any institution with access to organ donors consenting to tissue donation for research, and is an in

279 d by the same common law procedures used for consent to treatment.

280 Of 53 eligible surrogates, 32 (60%) consented to treatment allocation.

281 h a life expectancy greater than 4 weeks who consented to treatment with medication.

282 Of the 131 patients who consented to treatment, 29 patients spontaneously resolv

283 When consenting to treatment, few patients adequately underst

284 loan Kettering Cancer Center, 10336 patients consented to tumor DNA sequencing.

285 thods All participants gave written informed consent to undergo brain magnetic resonance imaging and

286 lot study, patients undergoing PCNL provided consent to undergo contrast-enhanced US and fluoroscopic

287 cer who had undergone breast MR imaging gave consent to undergo DE CE digital mammography.

288 prospective donors provide adequate informed consent to undergo the procedure.

289 hirty women undergoing screening mammography consented to undergo a repeated left craniocaudal examin

290 A subset of seven patients also consented to undergo BAL.

291 eligible and evaluable subjects, all of whom consented to undergo both digital and screen-film mammog

292 Of 47 patients approached, 42 consented to undergo detailed neurological evaluations i

293 Of the remaining 162 patients who consented to undergo randomization, 80 were assigned to

294 5 lesions after DCE MR imaging prospectively consented to undergo SWE during second-look US.

295 ed the study and waived the need for patient consent to use all images.

296 women and 318 infants in the placebo group (consent to use data was withdrawn for 1 woman and 2 infa

297 Written consent to use examinations was obtained from patients.

298 fewer than one third of eligible individuals consented to vaccination.

299 indings (Glasgow Coma Scale score 13-15) who consented to venepuncture within 24 h post injury and wh

300 microarray finding, 51 (10%) couples did not consent to WES or withdrew consent, and five (1%) sample